When Mistakes Happen…

Medical error has been described as a public health emergency. Certainly, the numbers support this. Opioid abuse – today’s exemplar of public health emergency – claimed an estimated 42,000 Americans in 2016, or about 115...

Online Exclusives

Telehealth Services Pose Privacy Concerns

Retailers – from Amazon to Walmart – are expanding their health-care services to include virtual visits with health-care professionals. While convenient for patients, the...

Cutting Patient Protections to Cut Costs?

The Trump administration proposed that reducing guaranteed coverage of certain drugs for Medicare beneficiaries would lower costs. The coverage requirement has been in place...

News

From the Blood Journals

WIB_icon

Preventing Hepatitis B Virus Reactivation During Immunochemotherapy for Lymphoma

Administering prophylactic antiviral treatment is effective in preventing hepatitis B virus (HBV) reactivation in patients with B-cell non-Hodgkin lymphoma (NHL) being treated with an...
WIB_icon

Do Children With CVC-Related Thromboses Need Anticoagulation Treatment?

Results from a prospective study of children who were hospitalized in a pediatric intensive care unit (PICU) revealed that the incidence of central vein...

Multimedia

PERIOP 2: Do Patients at High Risk for Arterial Thromboembolism Need...

Michael Kovacs, MD, discusses results from the PERIOP 2 trial, which found that post-procedure bridging with low-molecular weight heparin during warfarin interruption offered no...

A New Personalized Risk-Stratification Model for Myelodysplastic Syndromes

Dr. Nazha discusses a new tool for the risk-stratification of patients with myelodysplastic syndromes, which outperformed traditional risk models.

Evaluating a Venetoclax and Carfilzomib Combination in Myeloma

Luciano Costa, MD, PhD, shares findings from a phase II study, in which the combination appeared tolerable and effective in patients with relapsed/refractory myeloma.

Is Luspatercept a New Option for Patients With MDS?

Dr. List discusses results from the MEDALIST trial in patients with transfusion-dependent myelodysplastic syndromes, which were presented as a plenary abstract at the 2018...

On Location

Rivaroxaban Reduces Thrombotic Risk in Patients Undergoing Cancer Treatment

Primary prevention with the direct oral anticoagulant (DOAC) rivaroxaban reduced venous thromboembolism (VTE) and VTE-related...

New Tool Provides Simple Approach to Pausing Direct Oral Anticoagulants for Surgery

Researchers have developed a “simple, standardized, easy-to-use” strategy to guide decisions about interrupting direct oral...

Good News on the HORIZON: Melflufen Induces Response in Heavily Refractory Myeloma

One-third of patients with relapsed/refractory multiple myeloma (MM) that was refractory to pomalidomide and/or daratumumab...

For Older Patients With CLL, Ibrutinib Beats Standard Chemoimmunotherapy

Results from a randomized phase III study indicate that the Bruton tyrosine kinase (BTK) inhibitor...

Can Voxelotor Offer New HOPE for Sickle Cell Disease?

Treatment with voxelotor led to a dose-dependent increase in hemoglobin (Hb) levels in patients with...

Apixaban Superior to LMWH in Reducing Recurrence of Cancer-Associated VTE

Results from a trial presented at the 2018 ASH Annual Meeting add more support for...

Latest Headlines

Advertisement

ASH Directions

ASH Announces New Executive Committee Members, Hosts MDS+AML MATTER Education Program, and more

And The Winners Are … ASH has announced the election of four new members to its Executive Committee for terms beginning after the 2018 ASH...

Nancy Berliner Named Next Editor-in-Chief of Blood, and more

ASH Launches New Sickle Cell Disease Clinical Trials Network  ASH has announced the launch of a clinical trials network in sickle cell disease (SCD) to...

Sign up for our
eNewsletter!

ASH Presents Honorific Awards, Immunotherapy Researchers Receive Nobel Prize in Medicine, and more

American Society of Hematology Honors Distinguished Leaders at Annual Meeting At its 60th annual meeting, the American Society of Hematology (ASH) will present several distinguished...

Lili Yang Wins $1.4 Million CIRM Quest Discovery Grant, and more

Remembering Thomas Michael Przybysz (1951-2018)  Thomas Michael Przybysz, MD, an oncologist, passed away on July 19, 2018, at the age of 66. After serving in the...

Jonas Sokolof Named Director of NYU Langone’s New Rehab Program for Cancer Survivors, and...

Jonas Sokolof Appointed Director of NYU Langone’s New Rehabilitation Program for Cancer Survivors  NYU Langone’s Rusk Rehabilitation has opened the Division of Oncological Rehabilitation, launching...

When Mistakes Happen…

Medical error has been described as a public health emergency. Certainly, the numbers support this. Opioid abuse – today’s exemplar of public health emergency –...

Progress Report: Is the Moonshot Mission on Schedule?

A little less than three years ago, former President Barack Obama called on then Vice President Joseph Biden to lead the new National Cancer...

Hazardous to Your Health: Violence in the Health-Care Workplace

The headline-making events are familiar and chilling: a Boston cardiologist murdered in a hospital by the son of a deceased patient; an Indiana physician...